Compare AST SpaceMobile Inc (ASTS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? AST SpaceMobile Inc trades at $71.62 (market cap $20.54B), while Vertex Pharmaceuticals Incorporated trades at $529.7 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.5× AST SpaceMobile Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | VRTX | |
|---|---|---|
Market Cap | $20.54B | $132.79B |
Sector | Media | Health |
52-Week High | $133.09 | $529.59 |
52-Week Low | $36.91 | $374.46 |
Enterprise Value | $21.25B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.
Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
